| DB ID | MyCo_5936 |
| Title | Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience |
| Year | 2022 |
| PMID | 35819894 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Neutropaenic haemato-oncology patients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | Ethical approval was obtained from the Cambridge University Hospitals NHS Foundation Trust (UK) Audit Committee. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Cambridge University Hospitals NHS Foundation Trust is a British Committee for Standards in Haematology level 3 referral hospital offering outpatient and inpatient haemato-oncology services, including haematopoietic stem cell transplantation. In total, 302 patients were identified prior to the institution of the pathway and 308 patients after introduction of the pathway. The two cohorts were well matched in terms of sex, age, haematological diagnosis and transplant status. |
| Cohort No. | 610 |
| Age Group | 15-89 |
| P Value | p=0.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | PCR |
| Analysis Method | Serum Aspergillus PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Serum Aspergillus PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
